Geron could get lift from Sanofi's myelofibrosis troubles

Shares of Geron (GERN) are up 1.5% before the bell.

Although premarket volume is low, the stock could get a boost during the regular session from news that Sanofi has suspended studies of fedratinib.

For more on myelofibrosis, see here.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs